» Articles » PMID: 22852020

HCV and Lymphoproliferation

Overview
Date 2012 Aug 2
PMID 22852020
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatitis C virus (HCV) infection is a serious public health problem because of its worldwide diffusion and sequelae. It is not only a hepatotropic but also a lymphotropic agent and is responsible not only for liver injury--potentially evolving to cirrhosis and hepatocellular carcinoma--but also for a series of sometimes severely disabling extrahepatic diseases and, in particular, B-cell lymphoproliferative disorders. These latter range from benign, but prelymphomatous conditions, like mixed cryoglobulinemia, to frank lymphomas. Analogously with Helicobacter pylori related lymphomagenesis, the study of the effects of viral eradication confirmed the etiopathogenetic role of HCV and showed it is an ideal model for better understanding of the molecular mechanisms involved. Concerning these latter, several hypotheses have been proposed over the past two decades which are not mutually exclusive. These hypotheses have variously emphasized the important role played by sustained stimulation of the immune system by HCV, infection of the lymphatic cells, viral proteins, chromosomal aberrations, cytokines, or microRNA molecules. In this paper we describe the main hypotheses that have been proposed with the corresponding principal supporting data.

Citing Articles

Hepatitis C and Thalassemia: A Story with (Almost) a Happy Ending.

Origa R Pathogens. 2023; 12(5).

PMID: 37242353 PMC: 10223616. DOI: 10.3390/pathogens12050683.


Hepatitis Virus C-associated Nephropathy: A Review and Update.

Habas Sr E, Farfar K, Errayes N, Habas A, Errayes M, Alfitori G Cureus. 2022; 14(7):e27322.

PMID: 36043014 PMC: 9412079. DOI: 10.7759/cureus.27322.


Association between Anti-Hepatitis C Viral Intervention Therapy and Risk of Sjögren's Syndrome: A National Retrospective Analysis.

Tung C, Chen Y, Chen Y J Clin Med. 2022; 11(15).

PMID: 35893350 PMC: 9332495. DOI: 10.3390/jcm11154259.


Pathogenesis and Treatment of T-Large Granular Lymphocytic Leukemia (T-LGLL) in the Setting of Rheumatic Disease.

Couette N, Jarjour W, Brammer J, Simon Meara A Front Oncol. 2022; 12:854499.

PMID: 35747794 PMC: 9209697. DOI: 10.3389/fonc.2022.854499.


Prevalence of Occult Hepatitis C Virus Infection in Egyptian Patients with Lymphoma: A New Vision.

Elkashef K, Emam W, Mesbah N, Abo-Elmatty D, Abdel-Hamed A Diagnostics (Basel). 2022; 12(4).

PMID: 35454063 PMC: 9029505. DOI: 10.3390/diagnostics12041015.


References
1.
Libra M, Mangano K, Anzaldi M, Quattrocchi C, Donia M, Marco R . Analysis of interleukin (IL)-1beta IL-1 receptor antagonist, soluble IL-1 receptor type II and IL-1 accessory protein in HCV-associated lymphoproliferative disorders. Oncol Rep. 2006; 15(5):1305-8. View

2.
Zignego A, Ferri C, Innocenti F, Giannini C, Monti M, Bellesi G . Lack of preferential localization of tumoral mass in B-cell non-Hodgkin's lymphoma associated with hepatitis C virus infection. Blood. 1997; 89(8):3066-8. View

3.
Kumar A . MicroRNA in HCV infection and liver cancer. Biochim Biophys Acta. 2011; 1809(11-12):694-9. DOI: 10.1016/j.bbagrm.2011.07.010. View

4.
Antonelli A, Ferri C, Ferrari S, Ruffilli I, Colaci M, Frascerra S . High serum levels of CXCL11 in mixed cryoglobulinemia are associated with increased circulating levels of interferon-γ. J Rheumatol. 2011; 38(9):1947-52. DOI: 10.3899/jrheum.110133. View

5.
Zignego A, Giannini C, Monti M, Gragnani L . Hepatitis C virus lymphotropism: lessons from a decade of studies. Dig Liver Dis. 2007; 39 Suppl 1:S38-45. DOI: 10.1016/s1590-8658(07)80009-0. View